tradingkey.logo

Vaxcyte Advances Adult And Infant Programs For Vax-31, A Potential Best-In-Class, Next-Generation Pneumococcal Conjugate Vaccine

ReutersJan 22, 2026 10:36 PM

- Vaxcyte Inc PCVX.O:

  • VAXCYTE ADVANCES ADULT AND INFANT PROGRAMS FOR VAX-31, A POTENTIAL BEST-IN-CLASS, NEXT-GENERATION PNEUMOCOCCAL CONJUGATE VACCINE

  • VAXCYTE: VAX-31 ADULT PHASE 3 NONINFERIORITY TRIAL (OPUS-1) CONTINUES TO ENROLL SUBJECTS, WITH TOPLINE DATA EXPECTED IN FOURTH QUARTER OF 2026

  • VAXCYTE: EXPECTS TO REPORT TOPLINE SAFETY, TOLERABILITY AND IMMUNOGENICITY DATA FROM BOTH OPUS-2 AND OPUS-3 PHASE 3 STUDIES IN FIRST HALF OF 2027

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI